Status:
ACTIVE_NOT_RECRUITING
HIV Drug Resistance Among Individuals Failing Tenofovir/Lamivudine and Dolutegravir First Line Regimen in Brazil
Lead Sponsor:
Federal University of São Paulo
Collaborating Sponsors:
Gilead Sciences
Conditions:
HIV
Drug
Eligibility:
All Genders
18-65 years
Brief Summary
Brazil was the first middle-income country to provide free and universal access to antiretroviral drugs to HIV infected individuals. Since 2014 local guidelines recommend that all HIV infected individ...
Detailed Description
SPECIFIC AIMS We are on the verge of the global rollout of the second-generation integrase strand-transfer inhibitor (INSTI) dolutegravir (DTG), as the World Health Organization (WHO) now recommends t...
Eligibility Criteria
Inclusion
- Patints starting first line anti HIV treatment with Tenofovir/laimudine + Dolutegravir
- No previous antiretroviral treatment
- ≥ 18 ≤ 65 y.o
Exclusion
- • Not to be able to understand and sign the informed consent form
Key Trial Info
Start Date :
September 1 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
October 1 2025
Estimated Enrollment :
2500 Patients enrolled
Trial Details
Trial ID
NCT04453436
Start Date
September 1 2023
End Date
October 1 2025
Last Update
August 8 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Laboratório de Retrovirologia, EP2
São Paulo, São Paulo, Brazil, 04039-032